Vorinostat

Generic Name: Vorinostat

Brand Names: Zolinza

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₀N_₂O_₃

CAS Number: 149647-78-9

Unique Ingredient Identifier: 58IFB293JI

Background: Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...

Indication: 用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。

Associated Conditions: Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma

Associated Therapies: -

Clinical Trials

Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Adult Favorable Prognosis Hodgkin Lymphoma
Adult Lymphocyte Depletion Hodgkin Lymphoma
Adult Lymphocyte Predominant Hodgkin Lymphoma
Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
Adult Nodular Sclerosis Hodgkin Lymphoma
Adult Unfavorable Prognosis Hodgkin Lymphoma
Adult Mixed Cellularity Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma

Interventions: Drug: vorinostat
Other: laboratory biomarker analysis

First Posted Date: 2005-08-19

Last Posted Date: 2014-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT00132028

Locations: 🇺🇸
Southwest Oncology Group (SWOG) Research Base, San Antonio, Texas, United States

Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Phase 2

Completed

Conditions: Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer

Interventions: Drug: vorinostat

First Posted Date: 2005-08-19

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00132067

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

Phase 3

Completed

Conditions: Mesothelioma
Lung Cancer

Interventions: Drug: Placebo
Drug: Vorinostat

First Posted Date: 2005-08-09

Last Posted Date: 2020-10-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 661

Registration Number: NCT00128102

An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Drug: vorinostat

First Posted Date: 2005-08-05

Last Posted Date: 2015-04-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 23

Registration Number: NCT00127101

A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: vorinostat

First Posted Date: 2005-08-05

Last Posted Date: 2022-09-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 18

Registration Number: NCT00127127

A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: vorinostat

First Posted Date: 2005-08-05

Last Posted Date: 2015-09-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 10

Registration Number: NCT00127140

Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: vorinostat

First Posted Date: 2005-07-21

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 28

Registration Number: NCT00121277

Locations: 🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Phase 2

Completed

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size
Extraocular Extension Melanoma
Iris Melanoma
Uveal Melanoma
Recurrent Intraocular Melanoma
Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: vorinostat

First Posted Date: 2005-07-21

Last Posted Date: 2019-01-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT00121225

Locations: 🇺🇸
Fox Chase Cancer Center, Rockledge, Pennsylvania, United States
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

and more 1 locations

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: vorinostat
Drug: bortezomib

First Posted Date: 2005-05-26

Last Posted Date: 2015-05-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 34

Registration Number: NCT00111813

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Prostate Cancer
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-12-17

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005634

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy